Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
Year: 2017
Type: article
Study design: Clinical Trial
Source: The Lancet Oncology
Authors: Georgina V Long, Victoria Atkinson, Jonathan S Cebon, Michael B Jameson, Bernie M Fitzharris, Catriona M McNeil, Andrew G Hill, Antoni Ribas, Michael B Atkins, John A Thompson, Wen-Jen Hwu, F Stephen Hodi, Alexander M Menzies, Alexander D Guminski, Richard Kefford, Benjamin Y Kong, Babak Tamjid, Archana Srivastava, Anna J Lomax, Mohammed Islam, Xinxin Shu, Scot Ebbinghaus, Nageatte Ibrahim, Matteo S Carlino
Institutions: The University of Sydney, Royal North Shore Hospital, Melanoma Institute Australia, The University of Queensland, Greenslopes Private Hospital, Gallipoli Medical Research Foundation, Austin Health, Olivia Newton-John Cancer Research Institute, Waikato Hospital, Christchurch Hospital, Canterbury District Health Board, Royal Prince Alfred Hospital, Chris O’Brien Lifehouse, University of California, Los Angeles, Georgetown Lombardi Comprehensive Cancer Center, University of Washington, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Westmead Hospital, Macquarie University, Blacktown & Mount Druitt Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2735117693